[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences executive Johanna Mercier reported a mix of option exercises and stock sales. On February 17, 2026, she exercised 25,000 non-qualified stock options, acquiring 25,000 shares of common stock at $66.64 per share through a derivative exercise.
That same day, she sold 18,405 shares at $154.182, 9,395 shares at $154.9105, and 200 shares at $155.62 in open-market transactions under a Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, she held 120,288 shares of common stock and 48,110 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 28,000 shares ($4,324,228)
Net Sell
5 txns
Insider
Mercier Johanna
Role
Chief Comm & Corp Aff Officer
Sold
28,000 shs ($4.32M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-qualified Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Exercise | Common Stock | 25,000 | $66.64 | $1.67M |
| Sale | Common Stock | 18,405 | $154.182 | $2.84M |
| Sale | Common Stock | 9,395 | $154.9105 | $1.46M |
| Sale | Common Stock | 200 | $155.62 | $31K |
Holdings After Transaction:
Non-qualified Stock Option (Right to Buy) — 48,110 shares (Direct);
Common Stock — 148,288 shares (Direct)
Footnotes (1)
- The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Sale prices for the transactions reported range from $153.565 to $154.56 Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Sale prices for the transactions reported range from $154.57 to $155.27 Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.